先声药业：主业利润高增创新持续验证

浙商证券2025-04-25

投资要点2024 年经调整利润快速增长，BD 落地凸显创新实力，看好创新平台价值持续验证下估值提升机会。业绩：经调整净利润高增长公司2024 年业绩：集团收入66.35 亿元（YOY0.4%），归母净利润7.33 亿元（YOY2.6%），将投资收益和出售资产收益等调整后公司2024 年经调整归母净利润约人民币10.18 亿元（YOY41.6%）。多款创新药取得进展：2024 年新增2 款创新药恩立...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530135603?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-25 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530135603","market":"hk","top_or_hot":-1,"title":"先声药业：主业利润高增 创新持续验证","media":"浙商证券","content":"<div>\n<p>投资要点2024 年经调整利润快速增长，BD 落地凸显创新实力，看好创新平台价值持续验证下估值提升机会。业绩：经调整净利润高增长公司2024 年业绩：集团收入66.35 亿元（YOY0.4%），归母净利润7.33 亿元（YOY2.6%），将投资收益和出售资产收益等调整后公司2024 年经调整归母净利润约人民币10.18 亿元（YOY41.6%）。多款创新药取得进展：2024 年新增2 款创新药恩立...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425201204a466d100&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>先声药业：主业利润高增 创新持续验证</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n先声药业：主业利润高增 创新持续验证\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425201204a466d100&s=b><strong>浙商证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>投资要点2024 年经调整利润快速增长，BD 落地凸显创新实力，看好创新平台价值持续验证下估值提升机会。业绩：经调整净利润高增长公司2024 年业绩：集团收入66.35 亿元（YOY0.4%），归母净利润7.33 亿元（YOY2.6%），将投资收益和出售资产收益等调整后公司2024 年经调整归母净利润约人民币10.18 亿元（YOY41.6%）。多款创新药取得进展：2024 年新增2 款创新药恩立...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425201204a466d100&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425201204a466d100&s=b","article_id":"2530135603","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425201204a466d100&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530135603","pubTimestamp":1745510400,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"投资要点2024 年经调整利润快速增长，BD 落地凸显创新实力，看好创新平台价值持续验证下估值提升机会。多款创新药取得进展：2024 年新增2 款创新药恩立妥和先必新舌下片获批上市，新增3 款创新药恩泽舒、科唯可、玛氘诺沙韦片新药NDA 获受理。我们仍然看好2025-2027 年创新药板块收入在存量品种恩度、艾拉莫德、先必新、曲拉西利等持续放量，新增产品恩立妥、先必新舌下片、恩泽舒、科唯可驱动下保持较高增速，创新药占比持续提升趋势。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","02096":"先声药业","BK1191":"制药"},"translate_title":"Simcere Pharmaceuticals: High growth in main business profits and continuous verification of innovation","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"投资要点2024 年经调整利润快速增长，BD 落地凸显创新实力，看好创新平台价值持续验证下估值提升机会。业绩：经调整净利润高增长公司2024 年业绩：集团收入66.35 亿元（YOY0.4%），归母净利润7.33 亿元（YOY2.6%），将投资收益和出售资产收益等调整后公司2024 年经调整归母净利润约人民币10.18 亿元（YOY41.6%）。多款创新药取得进展：2024 年新增2 款创新药恩立妥和先必新舌下片获批上市，新增3 款创新药恩泽舒、科唯可、玛氘诺沙韦片新药NDA 获受理。此外，2024 年新增两款产品科赛拉（注射用盐酸曲拉西利）及恩立妥（西妥昔单抗β注射液）成功纳入NRDL，先必新（依达拉奉右莰醇注射用浓溶液）成功续约NRDL。创新：看好创新占比持续提升，BD 落地提升估值创新药占比提升趋势强：2024 年创新药业务收入49.28 亿元（YOY3.6%），创新药业务收入占总收入比例74.3%。我们仍然看好2025-2027 年创新药板块收入在存量品种恩度、艾拉莫德、先必新、曲拉西利等持续放量，新增产品恩立妥、先必新舌下片、恩泽舒、科唯可驱动下保持较高增速，创新药占比持续提升趋势。BD 落地凸显创新实力。2025 年1 月13 日，公司与AbbVie 的附属公司订立许可选择权协议，AbbVie 将拥有研究性新候选药物SIM0500（GPRC5D-BCMA-CD3三特异性抗体）的许可选择性权益。验证了公司创新技术平台的实力，我们也期待更多管线BD 落地，带来创新估值提升机会。盈利预测与估值我们预计2025-2027 年公司EPS 为0.43、0.55 和0.63 元，2025 年4 月24 日收盘价对应2025 年PE 为19 倍。我们仍然看好公司创新药存量+增量品种持续驱动2025-2027 年业绩保持快速增长，因此维持“买入”评级。风险提示临床失败风险，销售不及预期风险，政策风险","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530135603","isCrawlerRequest":true}

先声药业：主业利润高增 创新持续验证

精彩评论

先声药业：主业利润高增创新持续验证